CRISPR Therapeutics AG (CRSP) Preferred Stock Liabilities (2015 - 2016)

CRISPR Therapeutics AG has disclosed Preferred Stock Liabilities across 2 years of filings, most recently posting $1.2 million for Q3 2016.

• Preferred Stock Liabilities for Q3 2016 came in at $1.2 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2016 was $1.2 million (changed N/A YoY), and the FY2015 annual result was $10.4 million, up 103.76% from the prior year.
• Preferred Stock Liabilities came in at $1.2 million for Q3 2016 at CRISPR Therapeutics AG, down from $10.4 million in the prior quarter.
• In the past five years, Preferred Stock Liabilities ranged from a high of $10.4 million in Q4 2015 to a low of $1.2 million in Q3 2016.